Cumberland pharmaceuticals launches reditrex® product line for active rheumatoid, juvenile idiopathic and severe psoriatic arthritis

Nashville, tenn., sept. 29, 2021 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company, announced today the national launch of its reditrex ® (methotrexate) line of pre-filled syringes designed for the safe and simple treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis.
CPIX Ratings Summary
CPIX Quant Ranking